Taken together, our data illustrate an important role for HDAC11 in cell cycle progression and viability of MYCN-amplified neuroblastoma cells, and illuminates HDAC11 as a potential novel drug target for this subgroup of high-risk neuroblastomas. The gene discussed is MYCN; the disease is neuroblastoma.